Advanced Glycation End-Products in Complications of Diabetes Mellitus

被引：4
作者：
Parmaksiz, Ilker [1 ]
机构：
[1] Gaziantep Med Pk, Biyokimya, Gaziantep, Turkey
来源：
MARMARA MEDICAL JOURNAL | 2011年 / 24卷 / 03期
关键词：
Diabetes Mellitus; Advanced glycation end products; Treatment;
D O I：
10.5472/MMJ.2011.0.2037.1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetes mellitus is a metabolic disease, which results in microvascular and macrovascular complications in later stages. It has been known that with elevated glucose concentrations, proteins in both the circulation and the tissues are non-enzymatically glycated and this results in the production of advanced glycation end-products. Advanced glycation end-products alter cell structure and function which lead to the synthesis and release of cytokines and growth factors. Therefore, advanced glycation end-products contribute to the microvascular and macrovascular complications of diabetes mellitus. Inhibition of advanced glycation was found to reduce diabetic complications such as nephropathy, retinopathy and neuropathy. Some of the agents that are used for the treatment of advanced glycation end-products formation and accumulation are summarized in this review.
引用
收藏
页码：141 / 148
页数：8
相关论文
共 41 条
[1]   Advanced glycation endproducts - role in pathology of diabetic complications [J].
Ahmed, N .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 67 (01) :3-21
[2]  
Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS62, DOI [10.2337/dc09-S062, 10.2337/dc12-S064, 10.2337/dc11-S011]
[3]   Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine [J].
Babaei-Jadidi, R ;
Karachalias, N ;
Ahmed, N ;
Battah, S ;
Thornalley, PJ .
DIABETES, 2003, 52 (08) :2110-2120
[4]   Metformin reduces systemic methylglyoxal levels in type 2 diabetes [J].
Beisswenger, PJ ;
Howell, SK ;
Touchette, AD ;
Lal, S ;
Szwergold, BS .
DIABETES, 1999, 48 (01) :198-202
[5]   AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept [J].
Bierhaus, A ;
Hofmann, MA ;
Ziegler, R ;
Nawroth, PP .
CARDIOVASCULAR RESEARCH, 1998, 37 (03) :586-600
[6]   MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY [J].
BUCALA, R ;
MAKITA, Z ;
VEGA, G ;
GRUNDY, S ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9441-9445
[7]   The paraoxonases: role in human diseases and methodological difficulties in measurement [J].
Camps, Jordi ;
Marsillach, Judit ;
Joven, Jorge .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2009, 46 (02) :83-106
[8]   Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy [J].
Chabroux, S. ;
Canoui-Poitrine, F. ;
Reffet, S. ;
Mills-Joncour, G. ;
Morelon, E. ;
Colin, C. ;
Thivolet, C. .
DIABETES & METABOLISM, 2010, 36 (02) :152-157
[9]   Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats [J].
Cheng, G. ;
Wang, L-L ;
Long, L. ;
Liu, H-Y ;
Cui, H. ;
Qu, W-S ;
Li, S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (08) :1196-1206
[10]   Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy [J].
Chibber, R ;
Molinatti, PA ;
Rosatto, N ;
Lambourne, B ;
Kohner, EM .
DIABETOLOGIA, 1997, 40 (02) :156-164
12345